Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
Interventions: RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide; Drug
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 32
States / cities: Phoenix, Arizona • Duarte, California • Irvine, California + 27 more

Conditions: Colorectal Cancer, Colorectal Carcinoma
Interventions: Fecal Immunochemical Test (FIT) Kit, Culturally targeted Photo Novella Booklet, Screen for Life Brochure; Other · Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 50 Years to 75 Years
Enrollment: 331 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Fibromyalgia
Interventions: pregabalin, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 109
States / cities: Anniston, Alabama • Birmingham, Alabama • Calera, Alabama + 91 more

Conditions: HIV-associated Myelopathy
Interventions: Intravenous Immunoglobulin, Placebo; Drug
Lead sponsor: David M. Simpson; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
Interventions: Pramlintide, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Autoimmune Diseases, Mental Disorders Diagnosed in Childhood, Schizophrenia
Interventions: Intravenous immunoglobulin; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: Onartuzumab, Bevacizumab, Paclitaxel, Bevacizumab Placebo, Onartuzumab Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 23
States / cities: Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more

Conditions: Psoriatic Arthritis
Interventions: Guselkumab, Ustekinumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: Huntsville, Alabama • Trumbull, Connecticut • Clearwater, Florida + 9 more

Conditions: Diabetes Mellitus, Type 2
Interventions: placebo to match albiglutide, albiglutide, metformin, glimepiride, pioglitazone, placebo to match pioglitazone; Drug · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 685 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 321
States / cities: Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 257 more

Conditions: Covid19
Interventions: BNT162b2 vaccine, JNJ-78436735 Vaccine; Biological
Lead sponsor: Giselle Guerra; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: DNA CON-S env, IHV01, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus
Interventions: Lantus (insulin glargine [rDNA origin] injection), Metformin, Glyburide, Thiazolidinedione; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Emotional Dysregulation
Interventions: N-Acetyl Cysteine (NAC), Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 12 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions: Ramucirumab, Capecitabine, Cisplatin, Placebo, Fluorouracil; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 25
States / cities: Fayetteville, Arkansas • Bakersfield, California • Fullerton, California + 19 more

Conditions: Psoriatic Arthritis
Interventions: Tofacitinib 5 mg BID, Tofacitinib 10 mg BID, Adalimumab, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 24
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 17 more

Conditions: Renal Cell Carcinoma, Metastatic
Interventions: Intuvax (INN: ilixadencel), Sunitinib; Biological · Drug
Lead sponsor: Mendus; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 5
States / cities: Chicago, Illinois • Iowa City, Iowa • Saint Paul, Minnesota + 1 more

Conditions: Insulin Resistance
Interventions: Calorie Restriction, Control (normal living); Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 45 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cytokine Storm, COVID-19
Interventions: Anakinra, Normal saline; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Peripheral Neuropathy, Chemotherapy-induced
Interventions: PROCRIT 40,000 IU QW, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 28
States / cities: Mobile, Alabama • Little Rock, Arkansas • Alhambra, California + 25 more

Conditions: Sleep Disorder, Traumatic Brain Injury
Interventions: Branched Chain Amino Acids, Rice Protein, Microcrystalline Cellulose; Dietary Supplement
Lead sponsor: Portland VA Medical Center; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anxiety Disorder, Depression, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: minocycline hydrochloride, placebo, laboratory biomarker analysis, Questionnaire administration; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prostate Cancer
Interventions: Degarelix, Leuprolide; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 59
States / cities: Alexander City, Alabama • Homewood, Alabama • Anaheim, California + 54 more

Conditions: Diabetes Mellitus
Interventions: Insulin (recombinant human insulin), NovoLog; Drug
Lead sponsor: Nastech Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Oral Lichen Planus
Interventions: Curcuminoids, Placebo; Drug
Lead sponsor: Nita Chainani Wu; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Increasing Access to Colorectal Cancer Testing (IACCT) for Blacks

Safety and Efficacy Study of Pregabalin in Fibromyalgia

A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)

A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes

COVID-19 3rd Dose Vaccine in Transplant Patients

Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults

Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment

The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)

Effects of Calorie Restriction on Accumulation of Old, Modified Proteins in Abdominally Obese Adults

Early Treatment of Cytokine Storm Syndrome in Covid-19

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Pilot Study of BCAA on Sleep

Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer

A Study of Degarelix in Patients With Prostate Cancer

A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients

A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus